中國安儲能源(02399.HK)完成配售5957.4萬股 淨籌2970萬港元
格隆匯1月15日丨中國安儲能源(02399.HK)宣佈根據認購協議之條款及條件,所有認購事項條件已於2025年1月15日達成及認購事項已於2025年1月15日完成。根據認購協議,公司於公吿日期已根據一般授權按每股認購股份0.50港元的認購價配發及發行5957.4萬股認購股份予認購人,佔公司經配發及發行認購股份擴大的公司已發行股本約1.96%。
認購事項所得款項總額為約2980萬港元及認購事項所得款項淨額為約2970萬港元。預期該等認購事項所得款項淨額將用於該公吿中所述的目的。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.